# Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia

> **NCT01457040** · PHASE2,PHASE3 · COMPLETED · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 200 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Stem Cell Transplantation, Hematopoietic

## Interventions

- **DRUG:** TBI+CY+VP-16
- **DRUG:** FA+TBI+CY+VP-16

## Key facts

- **NCT ID:** NCT01457040
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2015-12
- **Final completion:** 2016-12
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2017-10-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01457040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01457040, "Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01457040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*